JP2018509441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509441A5 JP2018509441A5 JP2017549601A JP2017549601A JP2018509441A5 JP 2018509441 A5 JP2018509441 A5 JP 2018509441A5 JP 2017549601 A JP2017549601 A JP 2017549601A JP 2017549601 A JP2017549601 A JP 2017549601A JP 2018509441 A5 JP2018509441 A5 JP 2018509441A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- bis
- diyl
- furan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002950 monocyclic group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 19
- 125000004122 cyclic group Chemical group 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 17
- 239000012453 solvate Substances 0.000 claims 17
- -1 2-acetylnaphtho [2,3-b] furan-4,9-diyl Chemical group 0.000 claims 14
- 125000003277 amino group Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- 125000003367 polycyclic group Chemical group 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 125000001821 azanediyl group Chemical group [H]N(*)* 0.000 claims 10
- 208000006332 Choriocarcinoma Diseases 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 7
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 claims 4
- HJLMLJBJKDHMMO-UHFFFAOYSA-N 2-[2-[[2-acetyl-9-[2-(carboxymethylamino)ethylcarbamoyloxy]benzo[f][1]benzofuran-4-yl]oxycarbonylamino]ethylamino]acetic acid Chemical compound C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCCNCC(=O)O)OC(=O)NCCNCC(=O)O HJLMLJBJKDHMMO-UHFFFAOYSA-N 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 4
- 125000001091 aminosulfinyl group Chemical group [H]N([H])S(*)=O 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 4
- 125000004585 polycyclic heterocycle group Chemical group 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 3
- VPNIMHNFUBXAGW-UHFFFAOYSA-N 3-[2-[[2-acetyl-9-[2-(2-carboxyethylamino)ethylcarbamoyloxy]benzo[f][1]benzofuran-4-yl]oxycarbonylamino]ethylamino]propanoic acid Chemical compound C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCCNCCC(=O)O)OC(=O)NCCNCCC(=O)O VPNIMHNFUBXAGW-UHFFFAOYSA-N 0.000 claims 3
- 206010000830 Acute leukaemia Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 206010004593 Bile duct cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 208000008383 Wilms tumor Diseases 0.000 claims 3
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 210000000232 gallbladder Anatomy 0.000 claims 3
- 201000010175 gallbladder cancer Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000025189 neoplasm of testis Diseases 0.000 claims 3
- 201000008026 nephroblastoma Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 201000008968 osteosarcoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 208000037244 polycythemia vera Diseases 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 125000000626 sulfinic acid group Chemical group 0.000 claims 3
- 125000000542 sulfonic acid group Chemical group 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 210000003741 urothelium Anatomy 0.000 claims 3
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000006585 (C6-C10) arylene group Chemical group 0.000 claims 2
- RFSZKTIJCPMVKE-UHFFFAOYSA-N C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCCCNCC(=O)O)OC(=O)NCCCNCC(=O)O Chemical compound C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCCCNCC(=O)O)OC(=O)NCCCNCC(=O)O RFSZKTIJCPMVKE-UHFFFAOYSA-N 0.000 claims 2
- LHQDIYDFTASUEB-UHFFFAOYSA-N C(C)(C)S(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(=O)(=O)C(C)C)=O)=O Chemical compound C(C)(C)S(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(=O)(=O)C(C)C)=O)=O LHQDIYDFTASUEB-UHFFFAOYSA-N 0.000 claims 2
- SQRXQSQQKXQWEG-UHFFFAOYSA-N C(N)(=O)OCCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCOC(N)=O)=O)=O Chemical compound C(N)(=O)OCCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCOC(N)=O)=O)=O SQRXQSQQKXQWEG-UHFFFAOYSA-N 0.000 claims 2
- URVYOASRJNYOIA-UHFFFAOYSA-N CN(S(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(N(C)C)(=O)=O)=O)=O)C Chemical compound CN(S(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(N(C)C)(=O)=O)=O)=O)C URVYOASRJNYOIA-UHFFFAOYSA-N 0.000 claims 2
- ONSYNSSQVPMOMT-UHFFFAOYSA-N COC(=O)NCCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCNC(=O)OC)=O)=O Chemical compound COC(=O)NCCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCNC(=O)OC)=O)=O ONSYNSSQVPMOMT-UHFFFAOYSA-N 0.000 claims 2
- DHUUEZHQQQSGGS-UHFFFAOYSA-N COC(=O)OCCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCOC(=O)OC)=O)=O Chemical compound COC(=O)OCCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCOC(=O)OC)=O)=O DHUUEZHQQQSGGS-UHFFFAOYSA-N 0.000 claims 2
- DXRMLSJXWKJKEB-UHFFFAOYSA-N CS(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(=O)(=O)C)=O)=O Chemical compound CS(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(=O)(=O)C)=O)=O DXRMLSJXWKJKEB-UHFFFAOYSA-N 0.000 claims 2
- BSAHRFGEMAWCRT-UHFFFAOYSA-N N1(CCC1)C(CNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCC(=O)N1CCC1)=O)=O)=O Chemical compound N1(CCC1)C(CNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCC(=O)N1CCC1)=O)=O)=O BSAHRFGEMAWCRT-UHFFFAOYSA-N 0.000 claims 2
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000005110 aryl thio group Chemical group 0.000 claims 2
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims 2
- 125000005366 cycloalkylthio group Chemical group 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- HITQCTVKAAOGST-UHFFFAOYSA-N 2-[[2-[3-[(2-acetyl-4-hydroxybenzo[f][1]benzofuran-9-yl)oxycarbonylamino]propylamino]acetyl]amino]acetic acid Chemical compound C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2O)OC(=O)NCCCNCC(=O)NCC(=O)O HITQCTVKAAOGST-UHFFFAOYSA-N 0.000 claims 1
- GZZWQBJOFVDZQM-ROUUACIJSA-N C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCC[C@@H](C(=O)O)NC)OC(=O)NCC[C@@H](C(=O)O)NC Chemical compound C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCC[C@@H](C(=O)O)NC)OC(=O)NCC[C@@H](C(=O)O)NC GZZWQBJOFVDZQM-ROUUACIJSA-N 0.000 claims 1
- FRVBPRKMQURABC-KBPBESRZSA-N C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NC[C@@H](C(=O)O)N)OC(=O)NC[C@@H](C(=O)O)N Chemical compound C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NC[C@@H](C(=O)O)N)OC(=O)NC[C@@H](C(=O)O)N FRVBPRKMQURABC-KBPBESRZSA-N 0.000 claims 1
- WNTHVJVQQJHRRT-UHFFFAOYSA-N C(N)(=O)OCCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCOC(N)=O)=O)=O Chemical compound C(N)(=O)OCCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCOC(N)=O)=O)=O WNTHVJVQQJHRRT-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- LEXYGGUKAOGOMN-UHFFFAOYSA-N CN(S(=O)(=O)CCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCS(N(C)C)(=O)=O)=O)=O)C Chemical compound CN(S(=O)(=O)CCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCS(N(C)C)(=O)=O)=O)=O)C LEXYGGUKAOGOMN-UHFFFAOYSA-N 0.000 claims 1
- DGKQRZUMPNPSTB-UHFFFAOYSA-N COC(=O)NCCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCNC(=O)OC)=O)=O Chemical compound COC(=O)NCCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCNC(=O)OC)=O)=O DGKQRZUMPNPSTB-UHFFFAOYSA-N 0.000 claims 1
- NGQRPUFWOKCNTP-UHFFFAOYSA-N COC(=O)OCCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCOC(=O)OC)=O)=O Chemical compound COC(=O)OCCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCOC(=O)OC)=O)=O NGQRPUFWOKCNTP-UHFFFAOYSA-N 0.000 claims 1
- DHOWCZMPXJJCSG-UHFFFAOYSA-N CS(=O)(=O)CCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCS(=O)(=O)C)=O)=O Chemical compound CS(=O)(=O)CCNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCCS(=O)(=O)C)=O)=O DHOWCZMPXJJCSG-UHFFFAOYSA-N 0.000 claims 1
- ASNBOTMUYLMGEK-UHFFFAOYSA-N N1(CCC1)C(CNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCC(=O)N1CCC1)=O)=O)=O Chemical compound N1(CCC1)C(CNCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCNCC(=O)N1CCC1)=O)=O)=O ASNBOTMUYLMGEK-UHFFFAOYSA-N 0.000 claims 1
- IULHQXGYXNNZNC-UHFFFAOYSA-N N1(CCCCC1)S(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(=O)(=O)N1CCCCC1)=O)=O Chemical compound N1(CCCCC1)S(=O)(=O)CCNCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCNCCS(=O)(=O)N1CCCCC1)=O)=O IULHQXGYXNNZNC-UHFFFAOYSA-N 0.000 claims 1
- WWTUITZNQSJNCH-UHFFFAOYSA-N O.O.Cl.C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCCNCC(=O)O)OC(=O)NCCNCC(=O)O Chemical compound O.O.Cl.C(C)(=O)C1=CC2=C(O1)C(=C1C=CC=CC1=C2OC(=O)NCCNCC(=O)O)OC(=O)NCCNCC(=O)O WWTUITZNQSJNCH-UHFFFAOYSA-N 0.000 claims 1
- LZKCVTLSSDLNLF-UHFFFAOYSA-N [2-acetyl-9-(2-aminoethylcarbamoyloxy)benzo[f][1]benzofuran-4-yl] N-(2-aminoethyl)carbamate Chemical compound NCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCN)=O)=O LZKCVTLSSDLNLF-UHFFFAOYSA-N 0.000 claims 1
- NQASOCXWRQWSOH-UHFFFAOYSA-N [2-acetyl-9-(3-aminopropylcarbamoyloxy)benzo[f][1]benzofuran-4-yl] N-(3-aminopropyl)carbamate Chemical compound NCCCNC(OC1=C2C=CC=CC2=C(C=2OC(=CC=21)C(C)=O)OC(NCCCN)=O)=O NQASOCXWRQWSOH-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-M alaninate Chemical compound CC(N)C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-M 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139077P | 2015-03-27 | 2015-03-27 | |
| US62/139,077 | 2015-03-27 | ||
| PCT/IB2016/051706 WO2016157052A1 (en) | 2015-03-27 | 2016-03-25 | Water-soluble prodrugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019221478A Division JP6885999B2 (ja) | 2015-03-27 | 2019-12-06 | 水溶性プロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509441A JP2018509441A (ja) | 2018-04-05 |
| JP2018509441A5 true JP2018509441A5 (enExample) | 2019-02-14 |
| JP6630364B2 JP6630364B2 (ja) | 2020-01-15 |
Family
ID=55650622
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549601A Expired - Fee Related JP6630364B2 (ja) | 2015-03-27 | 2016-03-25 | 水溶性プロドラッグ |
| JP2019221478A Expired - Fee Related JP6885999B2 (ja) | 2015-03-27 | 2019-12-06 | 水溶性プロドラッグ |
| JP2021081570A Pending JP2021120401A (ja) | 2015-03-27 | 2021-05-13 | 水溶性プロドラッグ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019221478A Expired - Fee Related JP6885999B2 (ja) | 2015-03-27 | 2019-12-06 | 水溶性プロドラッグ |
| JP2021081570A Pending JP2021120401A (ja) | 2015-03-27 | 2021-05-13 | 水溶性プロドラッグ |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10183925B2 (enExample) |
| EP (1) | EP3274346A1 (enExample) |
| JP (3) | JP6630364B2 (enExample) |
| CN (1) | CN107660202B (enExample) |
| CA (1) | CA2980845A1 (enExample) |
| TW (1) | TWI710555B (enExample) |
| WO (1) | WO2016157052A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6630364B2 (ja) | 2015-03-27 | 2020-01-15 | ボストン バイオメディカル， インコーポレイテッド | 水溶性プロドラッグ |
| JP6936214B2 (ja) | 2016-03-25 | 2021-09-15 | 大日本住友製薬株式会社 | ２−アルキルカルボニルナフト［２，３−ｂ］フラン−４，９−ジオンの関連物質の製造方法、及びその関連物質 |
| WO2018102427A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| JP2020520923A (ja) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル， インコーポレイテッド | がんを処置するための方法 |
| EP3686182A4 (en) | 2017-09-22 | 2021-06-09 | Sumitomo Dainippon Pharma Co., Ltd. | CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG |
| US20220304972A1 (en) * | 2019-08-23 | 2022-09-29 | Sumitomo Dainippon Pharma Co., Ltd. | Combination therapy and biomarker indicating efficacy thereof |
| FR3112145A1 (fr) * | 2020-07-03 | 2022-01-07 | Nanotracks Diagnostics | Derives uree de macrolides polyeniques, composes chimiques particuliers susceptibles d’etre utilises pour obtenir ces derives uree, compositions les contenant et utilisations |
| WO2022003181A1 (fr) * | 2020-07-03 | 2022-01-06 | Nanotracks Diagnostics | Derivés urée de l'amphotéricine amb, compositions les contenant et leurs utilisations, dérivés isocyanate d'alkyle omega-aminés et leur utilisation pour obtenir lesdits dérivés urée |
| CN112194598B (zh) * | 2020-10-15 | 2021-12-21 | 郑州猫眼农业科技有限公司 | 3-(叔丁氧基羰基-r氧基羰基甲基-氨基)-丙酸酯的制备方法 |
| WO2023080258A1 (ja) * | 2021-11-08 | 2023-05-11 | 旭化成株式会社 | カルボニル化合物、カルボニル化合物の製造方法、イソシアネート化合物の製造方法、及びイソシアネート組成物 |
| CN118302407A (zh) * | 2021-11-08 | 2024-07-05 | 旭化成株式会社 | 羰基化合物、羰基化合物的制造方法、异氰酸酯化合物的制造方法以及异氰酸酯组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2736564A1 (en) | 2007-09-10 | 2009-03-19 | Boston Biomedical, Inc. | Novel compositions and methods for cancer treatment |
| US9150530B2 (en) | 2011-03-04 | 2015-10-06 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies |
| CN104080449A (zh) * | 2012-02-17 | 2014-10-01 | 舟山海中洲新生药业有限公司 | 4，9-二羟基-萘并[2，3-b]呋喃脂肪酸酯衍生物的纳米颗粒水悬液的制备方法 |
| GB201203705D0 (en) | 2012-03-02 | 2012-04-18 | Kappa Bioscience As | Prodrugs |
| WO2013166618A1 (en) * | 2012-05-08 | 2013-11-14 | Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. | PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE |
| JP6630364B2 (ja) * | 2015-03-27 | 2020-01-15 | ボストン バイオメディカル， インコーポレイテッド | 水溶性プロドラッグ |
-
2016
- 2016-03-25 JP JP2017549601A patent/JP6630364B2/ja not_active Expired - Fee Related
- 2016-03-25 EP EP16714015.1A patent/EP3274346A1/en not_active Ceased
- 2016-03-25 US US15/561,828 patent/US10183925B2/en active Active
- 2016-03-25 WO PCT/IB2016/051706 patent/WO2016157052A1/en not_active Ceased
- 2016-03-25 CN CN201680030052.0A patent/CN107660202B/zh not_active Expired - Fee Related
- 2016-03-25 TW TW105109636A patent/TWI710555B/zh not_active IP Right Cessation
- 2016-03-25 CA CA2980845A patent/CA2980845A1/en not_active Abandoned
-
2018
- 2018-11-19 US US16/194,525 patent/US10800752B2/en not_active Expired - Fee Related
-
2019
- 2019-12-06 JP JP2019221478A patent/JP6885999B2/ja not_active Expired - Fee Related
-
2020
- 2020-08-28 US US17/005,597 patent/US11414394B2/en active Active
-
2021
- 2021-05-13 JP JP2021081570A patent/JP2021120401A/ja active Pending